Evotec SE (EVO) Stock Price & Analysis
Evotec SE (EVO) is trading at USD 1.5, down 2.28% today, as of October 23, 2026 at 15:54 UTC (US market open; quotes may be delayed), according to Nexqual market data.
EVO last closed at USD 1.54; today's session has ranged USD 1.5–1.53 on volume of 11,518 shares. Market capitalization is $534.83M, with a 52-week range of USD 1.33–4.27 (NMS). Source: Nexqual, retrieved October 23, 2026 at 16:24 UTC.
Also available as compact Markdown for AI agents: nexqual.com/EVO.md
Key facts (EVO)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (3 analysts), mean target USD 4.22 (range 2.01–6.66).
- Total return with dividends: 1Y -62.8% vs S&P 500 +14.7%; 5Y -93.7% vs S&P 500 +77.5%.
- Next earnings: 2026-11-05, EPS estimate USD -0.32, revenue estimate $139M.
Analysts (EVO)
Consensus Buy (mean 2.00 on a 1–5 scale), 3 analysts; mean target USD 4.22 (low 2.01, high 6.66).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | HC Wainwright & Co. | Reiterated | Buy | $4 |
| 2026-07-15 | HC Wainwright & Co. | Target lowered | Buy | $7 → $4 |
Total return (dividends reinvested) (EVO)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -62.8% | -93.7% |
| S&P 500 (SPY) | +14.7% | +77.5% |
| Per year | -62.8% | -42.6% |
| Volatility (annualized) | 57.8% | 58.8% |
| Max drawdown | -67.5% (Oct 2025→Oct 2026) | -94.3% (Oct 2021→Oct 2026) |
EVO suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Novo Nordisk (NVO) | “Based on the strength of our molecular CKD patient database, we have built four partnerships in kidney diseases in the last almost ten years with prominent pharmaceutical companies such as Bayer, Vifor (now "CSL Vifor"), Novo Nordisk, Eli Lilly, and Chinook (now a Novartis company).” |
| Partner | Sandoz | “Following changes in our financial profile, the facility was no longer aligned with our evolving funding strategy, At the end of 2025, we completed a share purchase agreement with Sandoz for the sale of 100% of the shares in Just - Evotec Biologics EU SAS together with several related agreements, which strengthened our liquidity position in 2025, particularly in light of the expected debt repayment in 2026.” |
| Partner | Evotec Biologics | “Following changes in our financial profile, the facility was no longer aligned with our evolving funding strategy, At the end of 2025, we completed a share purchase agreement with Sandoz for the sale of 100% of the shares in Just - Evotec Biologics EU SAS together with several related agreements, which strengthened our liquidity position in 2025, particularly in light of the expected debt repayment in 2026.” |
| Partner | Eli Lilly (LLY) | “Based on the strength of our molecular CKD patient database, we have built four partnerships in kidney diseases in the last almost ten years with prominent pharmaceutical companies such as Bayer, Vifor (now "CSL Vifor"), Novo Nordisk, Eli Lilly, and Chinook (now a Novartis company).” |
Quoted from the company's 20-F filed Apr 8, 2026.
EVO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.32 | $-0.20 | +53.7% | $138.7M | 2 |
| Next quarter (ends Dec 2026) | $-0.24 | $-0.04 | +585.7% | $144.8M | 1 |
| Current fiscal year (ends Dec 2026) | $-1.48 | $-1.10 | +33.5% | $598.8M | 2 |
| Next fiscal year (ends Dec 2027) | $0.07 | $-0.15 | -145.2% | $721.4M | 1 |
Key Statistics (as of October 23, 2026 at 16:24 UTC)
| Price | USD 1.5 |
|---|---|
| Change | ▼ 2.28% (down) |
| Previous Close | USD 1.54 |
| Open | USD 1.5 |
| Day Range | USD 1.5 – 1.53 |
| 52-Week Range | USD 1.33 – 4.27 |
| Volume | 11,518 shares |
| Market Cap | $534.83M |
| Exchange | NMS |
Technical Analysis (EVO)
Nexqual's technical model rates EVO "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of October 23, 2026 at 16:24 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 43.83 (neutral) |
| vs SMA50 | Below (USD 1.69) |
| MACD | -0.06 (negative) |
Analyst Ratings (EVO)
Wall Street analysts rate EVO "Buy" based on 3 analysts, with a mean price target of USD 4.22 (range USD 2.01–6.66), per Nexqual as of October 23, 2026 at 16:24 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 4.22 |
| High Target | USD 6.66 |
| Low Target | USD 2.01 |
| Buy / Hold / Sell | 2 / 1 / 0 |
Earnings (EVO)
| Next Earnings Date | 2026-11-05 |
|---|---|
| Revenue Estimate | $138.69M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.13 vs est -0.04 ▼ miss |
| 2026-03-31 | USD -0.35 vs est -0.18 ▼ miss |
| 2025-12-31 | USD 0.05 vs est 0.07 ▼ miss |
| 2025-09-30 | USD -0.12 vs est -0.17 ▲ beat |
Source: Nexqual, October 23, 2026 at 16:24 UTC.
Financials & Fundamentals (EVO)
| Total Revenue | $717.28M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -16.20% |
| Gross Margin | +8.46% |
| Operating Margin | -62.26% |
| Profit Margin | -27.47% |
| ROE | -26.07% |
| Debt / Equity | 0.71 |
| Current Ratio | 2.33 |
| Total Cash | $465.59M |
| Total Debt | $475.87M |
Source: Nexqual, October 23, 2026 at 16:24 UTC.
Financial Health Score (EVO)
Nexqual rates Evotec SE's overall financial health "Weak" across five dimensions, as of October 23, 2026 at 16:24 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Critical — Gross margin 8%, operating -62% (last 12 months) |
| Balance Sheet | Strong — EUR 466M cash vs EUR 476M debt |
| Cash Flow | Weak — Operating cash flow -EUR 115M (TTM) |
| Efficiency | Critical — ROE -26%, ROA -5.4% |
Ownership (EVO)
| Insider Ownership | +0.01% |
|---|---|
| Institutional Ownership | +0.80% |
| Shares Outstanding | 355.39M |
| Float | 293.94M |
| Short % of Float | +0.01% |
Source: Nexqual, October 23, 2026 at 16:24 UTC.
Leadership (EVO)
Evotec SE is led by Christian Wojczewski, CEO & Chairperson of the Management Board, per Nexqual as of October 23, 2026 at 16:24 UTC.
| CEO & Chairperson of the Management Board | Christian Wojczewski |
|---|---|
| CFO & Member of Management Board | Claire Hinshelwood |
| COO & Member of Management Board | Ingrid Mller |
| Senior Vice President of Programme Management & Clinical Operations | Ian M. Hunneyball |
| Executive Vice President | David Hallet |
Major Backers & Investors (EVO)
Notable institutional backers of Evotec SE include DCF Advisers, LLC, WCM Investment Management, LLC, ABC Arbitrage SA, according to Nexqual as of October 23, 2026 at 16:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| DCF Advisers, LLC | 0.33% |
| WCM Investment Management, LLC | 0.2% |
| ABC Arbitrage SA | 0.11% |
Source: Nexqual, October 23, 2026 at 16:24 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BHC | Bausch Health Companies Inc. | USD 6.34 | ▼ 2.31% |
| SUPN | Supernus Pharmaceuticals, Inc. | USD 40.29 | ▼ 4.24% |
| HCM | HUTCHMED (China) Limited | USD 14.32 | ▲ 0.25% |
| LQDA | Liquidia Corporation | USD 40.99 | ▲ 3.27% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.58 | ▼ 3.47% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 34.22 | ▼ 3.14% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 16:24 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt